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ABBREVIATIONS

ATP,

Adenosine triphosphate

Cbl,

Cobalamin

CoA,

Coenzyme A

(vitamin B^)

CPS I, mitochondrial carbamyl phosphate synthetase
CPS II,
GLC,
MW,

cytosolic carbamyl phosphate synthetase

gas-liquid chromatography
molecular weight

NAG,

N-acetylglutamate

NPG,

N-propionylglutamate

OTC,

ornithine transcarbamylase

PCC, propionyl CoA carboxylase

Abstract
Hyperammonemia is a frequent complication of inherited deficiencies
of^-ketothiolase,
mutase.

propionyl

CoA carboxylase,

To probe the biochemical basis

and methylmalonvl CoA

for such ammonia accumulation,

I have determined whether a variety of organic acids
esters)

inhibit urea cycle enzyme activities

tions of rat liver
enzyme)

(crude homogenates,

(and

in vitro

their CoA

in several orepara-

isolated mitochondria,

and in crude homogenates of human

liver.

Neither tiglate,

propionate, nor methylmalonate at concentrations as high as
inhibited c.arbamyl phosphate synthetase I
carbamylase

(OTC)

activities

in rat

esters of these organic acids also
activities

in this

reproducible,
activity.

(CPS I)

10 mil

or ornithine

liver homogenates.

trans-

Whereas the CoA

failed to impair OTC and arginase

tissue preparation,

they produced a significant,

concentration- and time-dependent

inhibition of CPS I

This effect was not overcome by addition of

activator, N-acetvlglutamate

and pure

(NAG),

the CPS I

hence it was not secondary to

the

previously reported inhibition of NAG synthetase by several organic
acids.

Michaelis-Menten analysis showed

potent inhibitor,

decreased

each of the CPS I

substrates

tne V

max

(ATP,

that propionyl CoA,

but did not alter the K

ammonium,

concentration-dependent inhibition of CPS

liver.

are involved in the

inhibitory effect.

's

for
A

I by propionyl CoA was also
from rat

liver

The addition of dithiothreitol

to the pure enzyme prior to assay resulted in a decrease
of inhibition seen with propionyl CoA,

m

and bicarbonate).

demonstrated in isolated mitochondria and pure enzyme
as well as homogenates from human

the most

in

the degree

implying that sulfhydryl groups
These data suggest

that

the

vii

hyperammonemia seen in infants with these disorders may result,
from direct

inhibition of CPS I by these acyl CoA esters.

in part,

Part

I;

The Organic Acidemias

and Hyperammonemia:

A Review

Inborn errors of amino acid metabolism include
orders as phenylketonuria and

tyrosinemia, which result

of aromatic amino acid metabolism;
which

result

such diverse dis¬
from defects

cystathionemia and homocystinuria,

from defects of sulfur-containing amino acid metabolism;

and maple syrup urine disease and isovaleric acidemia, which result
from defects

of branched-chain amino acid metabolism.

aminoacidopathies are
which are related

Most of

these

associated with high morbidity and mortality

to the accumulation of substrates proximal

to the

defect: of the single enzymatic step which characterizes each disease
Early

identification of these disorders may allow amelioration of

morbidity and mortality by decreasing the

(1).

the

amount of the offending

amino acids in the diet.
Disorders of branched-chain amino acid oxidation in which amino
acids do not accumulate have been called
Since

the "organic acidemias".

the initial steps of this pathway are

first

a transamination

to the corresponding keto acid and then an irreversible decarboxylation
to the corresponding organic acid,
tion step will result

any block distal to this decarboxyla¬

in the accumulation of these organic acids,

not of the parent amino or keto acids
The discovery of
by the development

(2).

the inherited "organic acidemias" was made possible

of new techniques

for identification and characteri¬

zation of these organic acids, namely gas-liquid chromatography
and mass spectometry in conjunction with GLC
colleagues

(4)

but

first used

these

techniques

(3).

In

1966,

(GLC)

Tanaka and

to identify isovaleric acid

2

in the blood and urine of a patient with

the "distinct odor of sweaty

feet" and a constellation of symptoms now considered
tic for several of these organic acidemias.

to be characteris¬

This clinical presenta¬

tion includes episodes of ketoacidosis with vomiting and lethargy,
and coma or other neurological manifestations
neurological abnormalities observed include:

(3).

The particular

a Werdnig-Hoffman-like

syndrome with infantile paralysis in a patient with ^-methylcrotonvl CoA
carboxylase deficiency

(5);

ataxia and choreoathetosis

with pyruvate carboxylase deficiency

(6);

and a familial dysautonomia-

like picture with an abnormal histamine stimulation
with propionyl CoA carboxylase
neurological problems

(PCC)

is unknown but

neurological dysfunction secondary
specific dysfunction as

deficiency

test

(7).

in a patient

The cause of these

they may reflect either a general

to severe metabolic acidosis or a

in the case of PCC deficiency where

amounts of propionyl CoA may substitute
biosynthesis

in a patient

for acetyl CoA in

increased

fatty acid

leading to the production of an abnormal myelin.

Among the many recognized organic acidemias,
acetoacetic acidemia,

propionic acidemia,

share many clinical and biochemical

three,

-me thy 1-

and methylmalonic acidemia,

features.

First,

each results

from a deficiency of one of three mitochondrial enzymes^ B-ketothiolase,
propionyl CoA carboxylase,

and methylmalony1 CoA mutase,

which catalyze successive steps
metabolism.

in the major pathway of propionate

Second, each of these disorders may present with a similar

clinical picture— severe acidosis with lethargy,
to thrive, mental
abnormalities

respectively,

and physical developmental

including neutropenia,

and osteoporosis.

Third,

anemia,

vomiting and failure

retardation, hematologic
and

thrombocytopenia,

each has been associated with hyperglycinemia.

'

.

3
Prior to the elucidation of the precise biochemical defect in these
disorders, children with deficiencies of each of these enzymes were said
to have the "ketotic hyperglcinemia syndrome".

In addition to hyper¬

glycinemia, these disorders are characterized by other biochemical
abnormalities, including hypoglycemia, long-chain ketonemia and ketonuria, and, as will be discussed further, hyperammonemia.

The cause of

these biochemical derangements is unknown, but they are almost certainly
seondary to the primary deficiency in organic acid degradation (8).
To understand the relationship between these primary defects and the
secondary biochemical abnormalities, it is necessary to examine the
major biochemical pathway of propionate metabolism.

(See Figure 1)

Isoleucine is transaminated and decarboxylated to the organic acid,
<X-keto-/'-methylvaleric acid which undergoes further metabolism including
addition to a Coenzyme A carrier and dehydrogenation to yield^K-methylacetoacetyl CoA.

The latter intermediate is split by ^"-ketothiolase

to yield propionyl and acetyl CoA’s.

Other compounds including valine,

threonine, methionine, odd chain fatty acids, and cholesterol side chains
are also metabolized to propionyl CoA.

Previously, it was thought

that valine entered the Kreb’s Cycle through methylmalonyl CoA directly,
but recent work has provided evidence that propionyl CoA is an obligate
intermediate in this pathway (9).

Propionyl CoA is carboxylated to

D-methylmalonyl CoA by propionyl CoA carboxylase, a biotin requiring
enzyme (10).

Because only the L-isomer of methylmalonyl CoA is a

substrate for methylmalonyl CoA mutase, D-methylmalonyl CoA undergoes
racemization to the L-isomer in a reaction catalyzed by methylmalonyl CoA
racemase.

Finally, L-methylmalonyl CoA undergoes isomerization to

succinyl CoA in a reaction catalyzed by methylmalonyl CoA mutase, a

■

.
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isoleucine

valine

1
0{ -keto-£?-methylvaleric

©<-keto isovaleric acid

acid

J'

I

o\ -methylbutyrl CoA

isobutyrl CoA

I

tiglyl CoA

methylacrylyl CoA

1
0( -methyl-i/^-hydroxybuty rl CoA

^-hydroxy isobutyrl CoA

i

%-ketothiol ase

ft -hydroxy isobutyric acid

I

methylmalonic semialdehyde

acetyl CoA

propionyl CoA
propionyl CoA carboxlase

Sf
D-methylmalonyl CoA
methylmalony1 CoA racemase
L-methylmalonyl CoA
methylmalonyl CoA mutase
succinyl CoA

Figure

1. Metabolism of the branched-chain amino acids
isoleucine

valine and
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vitamin B^-requring enzyme
Vitamin B^>

or more appropriately cobalamin

has been extensively studied
the different
Cbl is

abnormalities

and this work is
that

can

(cbl) , metabolism

important

in understanding

result in methylmalonic acidemia.

a cobalt containing vitamin with six cobalt-associated

it occurs in a natural
form,

(11).

cyanocobalamin

form, hydroxocobalamin

(CN-Cbl).

These

intrinsic

Cbl absorption in the

factor.

The intrinsic

binds to the mucosa of the terminal ileum,
release of

free cbl into

protein carrier,
the body

the blood.

the cobalamin vitamin is

2)

CoA mutase activity.

(Ado-Cbl),

the

it

Once

to a serum

to the cells of
inside

the

active

finally,

cells,
it

adenosylation

to methylcobalamin

for N^-methyltetrahydrofdate :

(Me-Cbl),

the cofactor

homocysteine methyltransferase ,

cytosolic enzyme in the pathway of sulfur-containing amino acid
interconversion.

to

cofactor for methylmalonyl

OH-Cbl can also be converted, by a pithway which

has not yet been elucidated,

degradation and folate

the

the mitochondria where

undergoes two enzyme-catalyzed reductions and,
yield 5'-deoxyadenosylcbl

the gastric

the cbl is bound

(See Figure

transported into

terminal ileum

resulting in

transcobalamin II, which transports

for metabolism and use.

form by

factor- cbl complex

finally

There,

active as

to their active

is dependent on the presence of a protein produced by
parietal cells,

and a synthetic

forms of cbl are not

coenzymes but must be converted by the body
modification of the sixth ligand.

(OH-Cbl),

ligands;

a key

Figure

2.

Intracellular metabolism of OH-Cbl

cofactors,
the

(see

following page)

cell by transcobalamin II.

OH-Cbl
Once

OH-Cbl enters the mitochondrion where
to Ado-Cbl,

the active

to active

is transported

inside
it

to

the cell,

is metabolized

cofactor for methylmalonyl CoA

mutase.

Alternatively,

where it

is metabolized to Me-Cbl

OH-Cbl may remain in the cytosol

not yet been elucidated).

(by a pathway which has

/

5

Figure

2.

Intracellular metabolism of OH-Cbl to active
(see figure legend on proceeding page)

cofactors,

.

8

Methylmalonic Acidemia

As mentioned above,

the organic acidemias

several secondary biochemical derangements,
hypoglycemia,

and hyperglycinemia.

indeed secondary to defects
demonstration of

Proof

are

characterized by

such as hyperammonemia,

that

these derangements

in organic metabolism first

the primary defects

required

are
the

in the pathway of propionate

metabolism.
It has long been known that cbl is
mutase activity
acid in

(11);

thus,

required

for methylmalony1 CoA

the increased amounts

of methylmalonic

the urine of patients with pernicious anemia

cbl deficiency for other reasons

(13)

were expected.

parenteral administration of physiologic amounts
fall in methylmalonate excretion.

(12),

However,

in

and with

In these reports,

of cbl led

1967,

to a dramatic

two groups

(14,15)

described patients with increased methylmalonate excretion who had
normal serum cbl concentrations.
a child who presented on
a weak cry,
who was

Stokke and colleagues

(14)

described

the second day of life with irritability,

decreased activity, hypotonia and irregular respirations

found on

with ketonuria,

laboratory examination
and transient

to have severe metabolic acidosis

thrombocytopenia.

Methylmalonic acid

was identified in this patient's urine by GLC and mass spectometry.
The patient was given a trial of cbl without clinical

response or decreased

methylmalonate excretion.

this child revealed

that C

14

-valine

and this led

Further laboratory work in

loading resulted in excretion of C

the investigators

methylmalonate was

secondary

to postulate that

14

-methylmalonate

the accumulation of

to a defect in protein catabolism.

The

‘

9

patient was
valine,

started on a diet low in methylmaIonate precursors

threonine,

and methionine)

and this

the clinical condition and reduction in
With this diet,
mg/24 hours to

resulted in

the

Because the patient had

(normal

improvement of

tendency toward acidosis.

the excretion of methylmalonic
100-200 mg/24 hours

(isoleucine,

acid

less

fell

from 800-1000

than 5 mg/24 hours).

two older sibs who had died in

the neonatal

period with similar clinical symptoms,

these

a "new"

responsible

for the increased

also described

two children with

inborn error of metabolism was

investigators

thought

that

excretion of methylmalonate.
Oberholzer and colleagues

(15)

persistent metabolic acidosis,

vomiting,

and physical and mental develop¬

mental retardation who had abnormally high methylmalonic acid excretion.
They showed that valine, protein,

or propionate

fall in plasma pH and bicarbonate

level,

and hypoglycemia.

In addition,

an increase

all three

white

leukocytes

in plasma ketones,

_In vitro tests with the

revealed abnormal propionate metabolism.

cells were incubated with propionyl CoA and NaHC^O^,

malonate was
fumaric,

formed in normal amounts,

or malic acids was

Morrow and colleagues
cluded

(16)

found.

When

C^-methyl-

but no conversion to succinic,

These

in cultured

to a

of these substances augmented

the much increased methylmalonate excretion.
two patients’

administration led

findings were

fibroblasts.

that these patients had a block in

the

confirmed by

These groups con¬

conversion of methylmalonate

to succinate but did not distinguish between a defect

in

the

racemase

or mutase.
Rosenberg and colleagues

(17)

provided

defect in the mutase enzyme in at least

indirect evidence

for a

some of these patients by studies

on a one year old boy with methylmalonic acidemia.

They,

too,

found

.

10

II

that C^-propionate

conversion to

from this patient, but
concluded

was negligible

that succinate oxidation was

that the block was between propionate

this patient was not

cbl-deficient,

parenteral CN-Cbl led

They

and succinate.

to a fall in excretion of methylmalonate

leukocytes.

for a mutase defect,

of cbl-responsiveness

Although

from

and an increase in the

oxidation to CO^ by intact

to providing indirect evidence
the concept

intact.

administration of large doses of

800-1200 mg/24 hours to 220-280 mg/24 hours,
amount of propionate

in leukocytes

In

addition

this work established

in patientswith methylmalonic acidemia.

The demonstration of "cbl-dependency"
malonic acidemia to be divided into those

allowed patients with methyl¬
that were cb1-responsive,

i.e.

showed decreased methylmalonate excretion with amelioration of symptoms
after administration of pharmacologic doses
of cb1-deficiency

(17-19),

and those

workers performed more detailed

that were not

acidemia in order to correlate

(22)

obtained leukocytes

oxidize propionate or methylmalonate.

However,

cantly increased in leukocytes after oral
Morrow and colleagues

(23)

Other

demonstrated

with

clinical

in vitro changes.

from a cbl-responsive

patient prior to cbl administration and showed

homogenates

(14,20,21).

(decreased methylmalonate excretion)

Hsia and colleagues

the absence

analyses on several of these patients

with cbl-responsive methylmalonic
responsiveness

of cbl despite

that they

failed

to

oxidation was signifi¬

administration of cbl.

Further,

that mutase activity in liver

from a patient with cbl-responsive methylmalonic acidemia

was increased

to normal with the addition of saturating concentrations

of Ado-Cbl to the incubation mixture.

These groups concluded that methyl¬

malonic acidemia was genetically heterogeneous with cbl-unresponsive
patients having a defect in

the mutase

apoenzyme and

the

cbl-responsive

11

patients having a defect either in Ado-Cbl synthesis or in the mutase
apoenzyme such that it had a decreased affinity
the latter two defects could,

for Ado-Cbl.

Either of

theoretically, be overcome with pharma¬

cologic doses of cbl.
Recently, much work has been done to characterize
responsive forms of methylmalonic acidemia

(24-29).

further the cbl-

To date,

four

classes of mutants with defective cbl metabolism have been discovered.
Mahoney and colleagues

(24)

first distinguished

two groups of cbl mutants,

designated cbl A and B, which were distinguished by their ability to
synthesize Ado-Cbl.

Both cbl A and B mutants were unable

Ado-Cbl in intact cells,

but in a broken cell system cbl A mutants had

normal Ado-Cbl synthesis.

These workers proposed

represented either a defect

that

in cbl transport across

membrane or an abnormality of the

cbl

Further work by Mahoney and Rosenberg
cbl C,

and Me-Cbl.

Fibroblasts

(25)

cbl A mutants

the mitochondrial

reductase system,

mutants probably had a defective adenosyltransferase

cbl mutants,

to synthesize

and

(see

that cbl B

Figure

2).

identified a third class of

in which there was defective

formation

of both Ado-

from cbl A and B mutants accumulated no Ado-Cbl,

but Me-Cbl metabolism and intracellular concntrations were normal.
the other hand,
or Me-Cbl.

cbl C mutants had undetectable

This

class of mutants was

thought

On

levels of either Adoto explain the previously

reported association of methylmalonic acidemia with homocystinemia and
cystathionemia

(26).

Gravel

and colleagues

Sendai virus-mediated heterokaryons
B,

showed

(27)

in work with inactivated

complementation between cbl A,

and C mutants demonstrating a genetic heterogeneity corresponding to

the biochemical heterogeneity.

'
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Recently, evidence
has been described

for a fourth class of cobalamin mutants,

(28).

Like

cbl C mutants,

mutase and methyltransferase activity,
Ado- and Me-Cbl;

cbl uptake

cbl C and D

Neither class has been characterized biochemical¬

is normal, however,

more early cytosolic steps

lack

indicative of an absence of both

by complementation experiments, however,

are genetically distinct.
ly;

the cbl D mutants

cbl D,

suggesting abnormalities in one or

in the intracellular pathway of cbl coenzyme

synthesis.
A fifth class of in vitro cbl-responsive mutants has been
which does not complement with mutase apoenzyme mutants
cbl metabolism.

Willard and Rosenberg

of apomutase mutants
designated mut
compared with
the enzyme

and have demonstrated

, have an altered K
10

“8

for its

(29)

M for controls),
cofactor.

Mut

have studied
that

for Ado-Cbl

and has normal
these

two groups

the cbl-responsive group,
(in the

reflecting decreased
mutants most

found

range

of

10

-A

M

affinity of

likely represent base-

pair substitutions which affect the Ado-Cbl binding site

of methylmalonyl

CoA mutase, but not the catalytic site.

on

Mut^ mutations,

the other

hand, have no residual mutase activity regardless of cofactor concentrations,
and may represent

a deletion or nonsense mutation which results

apoenzyme production or production of a non-functional protein.

in no

13
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Propionic Acidemia

In retrospect,
by Childs

the

first patient with propionic acidemia was

and colleagues

(30)

in

1961.

of propionic acid was not detected at

However,
that

life with vomiting,

and ketonuria which persisted throughout
resulted in a pyloromyotomy at
the patient continued

he was

the increased

found in the patient's urine and blood.

presented at eighteen hours of

infections;

increased excretion

time and the disease was

called "idiopathic hyperglycinemia" because of
concentrations

the

he was

age

to vomit,

the

ten days.

hyperpnea,

However,

failed to thrive,

During the

that the episodes of vomiting,

lethargy,

acidosis,

first week of life and
postoperatively

and had

readmitted at eight weeks of age.

and glycinuria.

glycine

This patient

At

admission,

frequent
that

found to have neutropenia, hypogammaglobulinemia,

and purpura,

described

time,

thrombocytopenia

it was

demonstrated

and ketosis could be terminated

by withdrawal of oral feedings and intravenous administration of a
glucose and electrolyte solution.
diet led

to the symptoms of

and glycinemia.
well

Reintroduction of protein

the acute

illness with

increased glycinuria

Challenge tests with the individual amino acids were

tolerated clinically except

threonine and valine,

for leucine, methionine,

all of which resulted

isoleucine,

in vomiting and lethargy.

The increased urinary glycine noted during these episodes
workers

into the

led

these

to question whether the clinical and laboratory abnormalities

were secondary to this

increase.

However,

administration of sodium

benzoate, which conjugates glycine to hippurate,

did not prevent pro¬

duction of the typical metabolic acidosis, ketosis, vomiting,
lethargy in response

to dietary protein loading despite

a fall

and
in

.

*

glycinuria and glycinemia.
infusion of glycine

Further,

other workers

into one of these patients

(31)

demonstrated

resulted in neutropenia,

but none of the other clinical or biochemical abnormalities.
groups concluded

that the

that

increased glycine was not

the

Both

cause of the

periodic illness, but was secondary to some other abnormality related

to

protein degradation.
Subsequent
a diet

control of the illness

in Childs'

low in the offending amino acids,

glycine concentrations

(32).

two years after initiation of
he had suffered a decreased

resulted

initial patient with
also in a fall in

Follow-up studies

(33)

this special diet

(age 4^)

frequency and severity

in this patient
revealed

of the periodic epi¬

sodes of ketosis, had no thrombocytopenia or neutropenia,
creased

infections.

However, his

growth was

weight well below the thirdpercentile,
development were delayed,
ability

and had de¬

retarded with a height

and

and his mental and physical

including the inability

to speak and the in¬

to walk without help.

Although the primary defect remained obscure

for many years,

"forms" of idiopathic ketotic hyperglycinemia were recognized.
two forms were called "acute" and "chronic" by Tanaka

(3)

and colleagues

(34)

acidosis unresponsive
The early age of onset

to alkali

and had

Hommes

a severe metabolic

therapy who died at

five days of age.

and the severity of the symptoms

characteristic of Tanaka's "acute" group.

Brandc and colleagues

sister of Childs'

These

described a neonate who presented with hypotonia,

areflexia, hyperventilation and grunting,

child are

two

and were

differentiated by their age of onset and severity of symptoms.

treme,

that

(35)

describe

original patient.

seen in this

At the other ex¬

their experience with the

She had positive urinary ketones

,
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at 44 hours of

life and was started on

offending amino acids.

She was

followed

had evidence of only mild osteoporosis,
no thrombocytopenia,
mild nature of
group.

anemia,

a special

formula low in

to age eight

at which time

but had normal height

or neutropenia,

the

and an IQ of

she

and weight,

125.

The

this child’s disease is characteristic of Tanaka’s "chronic"

In between these

two extremes were children like

Childs'

original

patient who survived the neonatal period but suffered severe mental and
physical retardation.

This clinical heterogeneity was paralleled by

a biochemical heterogeneity.

For example,

infants who were shown to

have propionic acidemia were originally described without hypergly¬
cinemia

(34)

and without ketosis

heterogeneity

led workers

(36).

to postulate

patients with propionic acidemia was
at the locus which controlled
In

1968,

Rosenberg and

This clinical and biochemical
that the spectrum of disease in

secondary to genetic heterogeneity

the primary defect in protein metabolism.

colleagues

(17)

noticed several similarities

between patients with "idiopathic hyperglycinemia"

and those with

methylmalonic acidemia including protein induced ketosis and
long-chain ketonuria,
ties led

and intermittent hyperglycinemia.

these workers

to postulate

that the defect

acidosis,

These similari¬

in idiopathic

hyperglycinemia was along the pathway of propionate metabolism, but
since no methylmalonate was

found in

the urine,

the block must be

proximal to the production of methylmalonyl CoA.
groups

(34,37)

The

finding by other

of increased propionic acid in the urine

patients with idiopathic hyperglycinemia suggested

and blood of

that the primary defect

in these children was a decrease in propionyl CoA carboxylase
activity.
was

Other indirect evidnece

found at autopsy of

for a defect

(PCC)

in the PCC enzyme

the patient described by Hommes

at which a
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fatty liver was found.
unusual

and

Analysis of the stored triglycerides revealed

straight chain fatty acids.

These odd-numbered fatty

acids were explained by a defect in the PCC enzyme resulting in a secon¬
dary increase in propionyl CoA which could serve as a substitute for
acetyl CoA as a primer in fatty acid biosynthesis.

In addition, products

of alternate pathways of propionyl CoA metabolism, butanone

(31)

and

propionylglycine (38), have been identified.
More direct evidence for PCC deficiency in patients with ketotic
hyperglycinemia came first from Hsia and colleagues (39) who demon¬
strated that peripheral leukocytes from a patient with propionic acidemia
could not oxidize propionate to C09 as well as leukocytes from controls,
although oxidation of methylmalonate was normal.

Ando and colleagues

(38) ,

in addition to confirming these _in vitro studies in fibroblasts from a
patient with propionic acidemia, demonstrated that in_ vivo conversion of
propionate to CC^ was defective.

Synthesis of radiolabeled CoA derivatives

of propionate and methylmalonate finally allowed direct measurement of
PCC activity.

Activity in leukocytes and cultured fibroblasts were

reported by several groups (38,40,41) who found less than 2% of normal
activity in each of three patients with propionic acidemia.
Analagous to methylmalonyl CoA mutase, propionyl CoA carboxylase
requires a coenzyme, biotin,

for activity.

Barnes and colleagues (42)

described a patient with propionic acidemia who was not biotin deficient,
but who responded clinically and biochemically to pharmacologic doses
of biotin (10 mg/ 24 hours).

This patient was maintained on a 0.1 gram

protein/ kg diet and then given an isoleucine load, 0.1 g/ kg, which
resulted in lethargy with metabolic acidosis, ketosis, hyperglycinemia
and increased plasma propionate.

This was repeated after giving 5 mg

*
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of biotin twice daily
value,

as well as

for five days.

the height

The

fasting plasma propionate

and duration of

the propionate

to isoleucine loading was

significantly decreased

of clinical symptoms.

the other hand,

and colleagues
was described

(40)

On

the appearance

the patient described by Hsia

did not respond to biotin supplements.

for methylmalonic acidemia,

to the apoenzyme of PCC through

Thus,

as

propionic acidemia has both

vitamin-responsive and vitamin-unresponsive

biotin ligase.

as was

response

forms.

The biotin is

linked

an £-amino group of lysine by an apoenzyme-

An altered ligase or a PCC attachment

site with decreased

affinity for biotin which could be overcome with increased biotin are
likely causes

for the biotin-responsive variants

Biotin-unresponsive mutants most

likely

of propionic acidemia.

represent

a mutation

resulting

in either a defective apoenzyme or absent enzyme production.
The clinical heterogeneity,

called "acute"

and "chronic" by Tanaka,

was not a function of this biotin-responsiveness, nor was
of the amount
"chronic"

of residual PCC activity since

form had less residual activity

Other work with

it the

result

some patients with the

than

those with

the "acute"

(43).

Sendai virus-induced heterokaryons demonstrated two major

complementation groups,

designated pec A and pcc C

(44).

However,

this

genetic heterogeneity cannot explain the clinical differences since each
complementation group is clinically heterogeneous.
same family with two affected sibs,
death,

while

one

that

the difference

fact, within the

child had severe

the other was asymptomatic with normal

Tanaka concluded

In

coma leading to

intelligence

(45).

in clinical expression depends

upon the balance between production and disposal of propionate, which
depends,

in turn,

ways of removal,

on the diet,

and on the existence of alternate path¬

probably during a critical period of brain growth in

.
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the neonate

(3).
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<X -methylacetoacetic Acidemia

In

1971, Daum and colleagues

(46)

described a child who presented

at 22 months of age with symptoms compatible with the known disorders

of

propionate metabolism except that he ahd normal propionate and methylmalonate

concentrations

abnormal amounts of

in the body fluids.

However,

child excreted

two other organic acids, cX-methylacetoacetic

©<-methyl-^-hydroxybutyric acids.

These workers

suggested that

had a new disorder of amino acid metabolism, which was

B-ketothiolase

this

deficiency.

This patient’s

clinical

only five episodes of ketoacidosis before age

and

this child

later shown to be

course was mild with

five years,

and normal

physical and mental development.
Other groups have subsequently described additional children with
these clinical and biochemical characteristics who had more
clinical findings.

Keating and colleagues

(47)

severe

described a child with

projectile vomiting who underwent pyloromyotomy but continued to voinit
exhibit

failure

to thrive postoperatively.

presented with lethargy,

At age three months, he

thrombocytopenia, hyperglycinemia and glycinuria,

osteoporosis, hyperammonemia and long-chain ketonuria,
responded to a restricted protein diet.
stabilization on this diet resulted in
and

all of which

Isoleucine challenge after
the recurrence

of

the

above

symptoms

findings.
Daum and colleagues

Keating's patient
acidemias,

and

(48)

reviewed the

and determined

that,

from their and

like propionic and methylmalonic

this new disorder could present

clinical and biochemical severity

two pedigrees

anywhere in a spectrum of

from mild intermittent episodes cf

ketoacidosis with normal growth and development

to severe

recurrent

'

■
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episodes characterized by intermittent vomiting, metabolic acidosis,
and the

other biochemical

syndrome.

These workers

coma

features of the ketotic hyperglycinemia

suspected

that the abnormal clinical and biochemical

findings were related to protein catabolism and demonstrated significant
increases

in

the abnormal urinary metabolites

loading.

They proposed

that

in response

the combination of

methylmalonate concentrations with
proximal to the,/}-ketothiolase

as a cause of this new disorder.

normal propionate

the buildup of

reaction,

to isoleucine

the

two substances

pointed to a defect in

to an equilibrium of the

versible interconversion reaction between the two compounds,
like

the acetoacetate/V?-hydroxybutyrate

NAD/NADH ratio in the

that enzyme

They proposed that the appearance

both of the abnormal metabolites was due

of which,

and

ratio,

of

re¬

the balance

depends on

the

cell.

The localization of the defect was demonstrated more directly by
Hillman and colleagues

(49)

who described a child who presented in the

first week of life with symptoms of the ketotic hyperglycinemia syndrome.
Metabolism of propionate and methylmalonate

in leukocytes and cultured

fibroblasts

However,

to C(>2 was

from this patient were normal.
less

than 40% of controls.

along with the appearance of butanone

oxidation of isoleucine

They concluded that
in

the urine

be a metabolite of<X-methylacetoacetic acid),

this

(which was

localized

finding,

thought

the defect

to the

/^-ketothiolase enzyme.
Gompertz and colleagues

(50)

described a child who presented

at

seven years of age having survived childhood with only complaints

of

frequent episodes of abdominal pain, headaches and vomiting.
measured tiglyl CoA-dependent incorporation of

to

They

tritiated water into

.
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propionate

in leukocytes of this patient and

in activity compared

to control cells.

two enzymes preceeding propionyl CoA in
degradation.

This

found a significant decrease
localized

the defect

the pathway of isoleucine

to one of
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Urea Cycle

The primary defects
way,

affect

the

in the pathways demonstrated above must,

turnover of ammonia in patients with

and lead to hyperammonemia.
production,

i.e.

This effect may be an

negative nitrogen balance,

pairment of the urea cycle,

or both.

in organic acid metabolism may
mechanism,

it is

in some

these organic acidemias

increase

decreased

in ammonia

removal,

i.e.

im¬

In order to understand how a defect

lead to hyperammonemia by this

first necessary to examine

the urea cycle,

latter

its enzymes,

and the control of its activity.
Ammonia is

formed primarily as

acid catabolism from the amide

the end product of amino and nucleic

groups of glutamine and asparagine,

amine groups of glutamate and aspartate,
guanine and their derivatives.
ureases

found in the normal

and the amino groups

of adenine,

In addition, microbial deaminases and

flora of

the

large intestine

cleave

amino acids

and urea to ammonia which is absorbed by the gut and contributes
blood ammonia pool.
neurological

To prevent

toxicity,

ammonia is used in

the buildup of ammonia and its

the deamination reactions.

to the

consequent

ammonia is removed via several pathways.

the synthesis

the

First.,

of amino acids by reversal of several of

In addition,

ammonia can be used

in purine,

pyrimidine and porphyrin synthesis via incorporation into glutamine,
carbamyl phosphate,
converted

and glycine.

Lastly,

into nitrogen containing organic

and most

important,

compounds,

urea in mammals

and uric acid in birds and reptiles, which are excreted
Urea is

formed

ammonia is

from the body.

in mammals via the urea cycle in which two moles of

ammonia and one mole of carbon dioxide

are

consumed

in

the production

.
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of one mole of urea through a pathway of intermediates.

That

is

1924 when

the major site of urea formation has been known since

Bollman and colleagues
experimental dogs
In

(51)

demonstrated that removal of the

led to a decreased urea concentration

1932, Krebs and Henseleit

biochemical

(52)

and carbon dioxide

(in the

in vitro in rat

the amino acids tested was ornithine.

in the blood.
initial

They demonstrated

liver slices

form of bicarbonate)

for other compounds that could act as

liver in

began the work in which the

steps of the urea cycle were discovered.

that urea could be synthesized

the liver

from ammonia

and this began a search

a nitrogen donor to urea.

One of

They found that one molecule of

ornithine stimulated the formation of 20 molecules of urea when ammonia
was present.
and

However,

the ornithine was not

consumed in the process

the total urea nitrogen could be accounted

ammonia.

for by the disappearing

These puzzling kinetics remained a mystery until

of a pathway in which ornithine,
form arginine.

carbon dioxide,

and ammonia combine

Along with the long known presence of an enzyme,

which catalyzes the reaction in which arginine is
and urea,

the discovery

split

the original ornithine cycle was proposed,

to

arginase,

into ornithine

(see Figure

3)

ornithine

NH,
CO,
arginine

Figure

3.

The original ornithine
in

1932

cycle as proposed by Krebs and Henseleit

/
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Further work has elucidated the urea cycle
Figure 4), with
cycle.

The

five reactions catalyzed by the

carbamyl phosphate.

by CPS I,

This

(see

five major enzymes of the

initial step in the urea cycle is the

of ammonia and one. mole of carbon dioxide
mediate,

as we now know it

fixation of one mole

to form a high energy inter¬

reaction

requires ATP and is catalyzed

an enzyme which uses ammonia as the nitrogen donor and which

found primarily in

the mitochondrial matrix of liver cells.

is distinct from CPS II,

This enzyme

an enzyme of pyrimidine biosynthesis

found in

the cytosol of most cells and which uses glutamine as a nitrogen donor
CPS I is a dimer of MW 250,000;
125,000

(54).

each subunit

This reaction requires,

mentioned above, Mg

+2

.

(needed

affinity of the enzyme

is

for its substrates)

consumed per mole of carbamyl phosphate

to the substrates

+

and K

(55).

formed:

(53).

identical with MW of

in addition

for ATP binding)

is

(increases

the

Two moles of ATP
one mole

is

are

consumed in

the dehydration of bicarbonate and yields a high energy intermediate
which adds

to ammonia to

be carbanyl phosphate;

form another high energy intermediate

and a second ATP

and Cohen

(57,58)

when

(56).

the CPS I

reaction was made by Grisolia

they demonstrated that this

glutamate derivative as an activator.
carbamyl glutamate, but six years
identified N-acetylglutamate

(NAG)

reaction

required a

Their initial experiments used

later. Hall and colleagues
as

to

that donates a phosphoryl group

to carbamate to yield carbamyl phosphate
An important discovery about

thought

(59)

the naturally occurring cofactor

for carbamyl phosphate synthesis in mammalian liver.

This was confirmed

by work which demonstrated the presence of NAG synthetase,
found in the mitochondrial matrix which

catalyzes

the

an enzyme

formation of NAG

25

Figure 4.

The urea cycle.

The mechanism of ammonia detoxification in

mammals involves the condensation of nitrogens from ammonia and aspartate
with CC^ to form urea tnrough the five enzyme cycle shown above.

)
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from L-glutamate and acetyl CoA and which is stimulated by L-arginine
NAG causes a conformational change
the enzyme

in CPS I which results

which catalyzes

MW 108,000;

(OTC)

is an intramitochondrial enzyme

the condensation reaction between carbamyl phosphate

ornithine to form citrulline
each subunit

is

(61).

binding sites

identical and of MW 36,000

for carbamyl phosphate

dissociation constants,

(62).

(one per subunit)

with

substantiates this earlier finding

three

different

(63).

Citrulline

this reaction is transported from the mitochondria to the

Cohen and Hayano first demonstrated that citrulline
verted to arginine in rat liver slices

+2

Although

the demonstration of three

cytosol on a specific carrier which is not energy dependent

that Mg

and

OTC from bovine liver is a trimer of

trimers are unusual in mammalian systems,

in

in activation of

(54).

Ornithine transcarbamylase

formed

(60) .

is required and

presence of oxaloacetate)

(65).

that either aspartate

(67)

demonstrated that

malic acid.

the second cleaved

this

demonstrated

or glutamate

(in

the

Much work was done

for this ammonium transfer.

two enzymes were

first catalyzed a condensation between citrulline
an intermediate;

could be con¬

(66)

acted as the nitrogen donor.

in elucidating the enzyme system responsible
Ratner and Pappas

Ratner

(64) .

required:

and aspartate

intermediate

to yield

to arginine and

This intermediate was identified as argininosuccinate

and the reaction required one mole of ATP per mole of product
The enzyme that

catalyzes

It is localized in

this

the cytosol

subunits each of MW 45,000

reaction is argininosuccinate
and has a MW of

(70).

is a pyrophosphatase which removes

the

180,000 with

(68)

formed

(69).

synthetase.
four identical

Associated with the synthetase enzyme
the inorganic phosphate

formed and pulls

efo

.
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the condensation reaction in
Argininosuccinase
succinate

the direction of product

(argininosuccinic acid lyase)

to arginine and fumaric acid

acid by earlier groups

(67)

(71).

(The

formation

cleaves arginino-

finding of malic

was believed to be secondary to the

present in the acetone-dried liver preparations used.)
is a tetramer of MW 202,000.
weighing 50,000 daltons each
chain

(68).

It contains
(72),

fumarases

Argininosuccinase

four identical subunits

with one catalytic site per polypeptide

(73).
Finally,

is a Mn

+2

arginase splits arginine

-requiring enzyme of MW

weighing 30,500 daltons each

into urea and ornithine.

118,000 with

(77).

four identical subunits

The ornithine

formed enters

chondria via an energy-dependent carrier which is specific
but not arginine"*" or lysine"*",

Arginase

and is stereospecific

the mito¬

for ornithine"1"

for L-ornithine

(67) .

Regulation of the Urea Cycle
The exact, mechanisms by which urea production is controlled
known despite a considerable amount of work in this area.
mechanism does exist has been known since

1905 when Folin

That
(75)

that urea production in normal adults was proportional to the
protein.

a control
demonstrated

intake of

Urea excretion fell within a day when a low protein diet in

the form of a "starch and

cream diet"

cream) was fed to his subjects;
when a regular diet was
The

are not

300 ml of

urea production increased within a day

reinstituted.

controversy over the

between those

(400 g pure starch and

control of urea production has been waged

investigators who believe that control

by changes in enzyme activities and those who believe
mediated by changes in substrate concentrations.

is mediated largely
that control

is

Nuzum and Snodgrass

(76)
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demonstrated that an increase in the protein content of a monkey’s diet
from 1.6 to 16 g protein/ kg resulted in a two to three fold increase in the
activity of all urea cycle enzymes in liver homogenates _in_ vitro.
ther, Schimke (77)

Fur¬

showed that this increase in enzyme activity was linearly

related to the increase in protein, and concluded that the increased urea
production was due to increased enzyme activity..

Schimke isolated

OTC and arginase from rats fed diets containing 15% and 60% protein and
showed that both enzymes had the same pH optima, K^’s for substrates,
MW, and turnover number regardless of the protein intake.

He concluded

that the increased activity of the urea cycle enzymes was due to an
increased number of protein molecules and not to a change in the kinetic
parameters of the molecules already present.

The activities of the non¬

urea cycle enzymes measured such as glutamate dehydrogenase were not elevated
at higher protein concentrations, so that the increase in urea cycle enzyme
activities was not a non-specific increase due to more available amino
acids for protein synthesis.

Schimke followed the time course of the

increase in activity and demonstrated that it was completed within four
days for OTC, CPS I, and argininosuccinase and within eight days for
arginase.
Other workers argued that the augmentation of urea production must
depend on the substrate load, not on the activity of the urea cycle enzymes,
since the rate of urea excretion demonstrated by Folin changed more rapidly
than the change in urea cycle enzyme activity described by Schimke.
In support of this concept is the work by McGivan and colleagues (78)
in which the rate of citrulline synthesis and the activities of the urea
cycle enzymes were measured under different dietary conditions.

In rats

.

.
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fed a high protein diet
was

increased 20

the

fold compared to rats

maximal activities of
under these

(egg whites),

rate of citrulline synthesis

fed 20% glucose.

the urea cycle enzymes did not

two dietary conditions.

and those of Nuzum and Snodgrass
Tatibana and Shigsada

(79)

composed of two enzymes,

CPS I

vators, NAG and arginine.

and Schimke

proposed that

(77)

the

reflect

production of NAG
glutamate); NAG,
(In addition,
substance.)
Tatibana

acetylglutamate-arginine system,

and NAG synthetase,

They believe

and their two acti¬

that glutamate

and arginine

stimulates

in these

of

a critical rate-limiting
Shigesada and

demonstrated that the NAG concnetration in mitochondria

percentage of the protein
NAG concentration
addition, when C

1A

in

the diet was

increased from 15
-glutamate was

30 minutes,

liver samples had

minutes,

the

the production of carbamyl phosphate.

In experiments with protein loaded mice,

This indicates

two

increased amount

increased in parallel with the increased protein in the diet.

sacrificed

are

Arginine stimulates

(which is accomplished because of the

arginine may supply ornithine,

(80)

results

regulation of urea

increased protein catabolism.

in turn,

these

remains unexplained.

representative of the amino acid pool and that increases
amino acids

the

differ greatly

The disparity between

(76)

production is accomplished via the

However,

3900,

two hours,
5900,

increased

to AO nmoles/ g liver tissue.

In

and nine hours

In

later, NAG isolated

from

respectively.

thirty

to explain the increased urea production

further support of this hypothesis,

demonstrated that the increase

the

injected into three mice who were

and 260 cpm per g wet weight liver,

a response quick enough

the

from zero to 60%,

that significant synthesis of NAG occurs within

described by Folin.

When

in NAG paralleled the

these workers

increase excretion

,

.

■
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of urea after protein loading

(79).

Further elaboration of this mechanism was
by Stewart and Walser

(81).

after an intraperitoneal
Glutamate

injection of a

activity peaked

Surprisingly,

in NAG was not

synthetase by arginine.
at least

According to this notion,

concluded that control

via control of glutamate

protein loading results

CPS I

of urea-

concentrations.

in increased

trations of glutamate which forms NAG and activates CPS I.
amino acids of 3 g/ kg,

indicating

secondary to an activation of NAG

These authors

in part,

five

this effect was

and equal with or without arginine in the mixture,

the increase

genesis was,

1.5 g/ kg mixture of amino acids.

as well as CPS I

to fifteen minutes after injection.

that

in recent work

Rats were sacrificed at certain time intervals

and NAG concentrations,

reproducible

reported

concen¬

At doses of

activity was maximally activated and reached

the same value seen in disrupted mitochondria with saturating concen¬
trations of NAG.

Moreover,

at doses of amino acids

from 3-5 g/ kg,

the

autoregulatory mechanism became saturated and hyperammonemia supervened.
Other authors have examined other steps
control sites.
ornithine

Krebs and colleagues

for OTC is

ornithine '.(0.3 mM)
in vivo.

1.4 mM,

makes

it

colleagues

(83)

(52) ,

suggest that since

as possible

the

of

the normal extracellular concentration of
likely that ornithine

This may explain the

on the urea cycle

(82)

in the urea cycle

is

rate-limiting

reported stimulatory effect of ornithine

as well as recent work reported by Batshaw and

in which arginine infusions

(as a source of ornithine)

resulted in a fall in blood ammonia in infants with argininosuccinic
aciduria.
Finally,
reagent

(84).

it has been suggested that ATP may be
In work in which animals were exposed

the

rate-limiting

to an anoxic

.

«
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challenge,
mal;

this was accompanied by a significant rise in blood ammonia.
Thus,

the

the concentration, of ATP was lowered to less than 10% of nor¬

the controversy continues between the

"substrate hypothesis".

"enzyme hypothesis" and

Changes in maximal enzyme activity as

measured in vitro do not occur fast enough to account for the increased
urea production,

but this in_ vitro work may not accurately reflect the

in vivo situation.

Increased substrate concentrations may lead to

increased urea production if enzymes are not fully saturated,

but the

in vivo effect of changes in substrate concentration awaits the accurate
determination of intramitochondrial concentrations and comparison to
values.

It is likely that a system as complex as the urea cycle is

regulated by changes in both substrate concentrations and enzyme activities.

*
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The Organic Acidemias

and

Several biochemical

cinemia,

Hyperammonemia

abnormalities

including

hypoglycemia and hyperammonemia are

inherited organic

primary defect

acidemias

and are

commonly

found

acidemia

(20,87,88),

to

in

finding

common

of

acidemia

and iX.-methylacetoacetic

and young

children.

secondary

these

the

The precise mechanism of

identified,

an attempt to

the primary enzymatic defect with this

is

and may

so often occurs

not yet been

it

methylmalonic

(47),

hyperammonemia has

link

to

disorders,

(85,86),

acidemia

the metabolic encephalopathy which

affected newborns

the

Although hyperammonemia has

in all

infants with propionic

hypergly¬

to each of

to occur

in organic acid metabolism.

not been considered a constant

contribute

thought

acidosis,

but much work has

in

this

been done

in

secondary

metabolic derangement.

Rosenberg

and

colleagues

two patients with propionic

in blood

(89).

demonstrated

acidemia resulted

ammonia values which were

This work

of propionate

in

suggested

that

posed

could directly

enzymes or damage

one of the

substrates

citrulline

transport

Since

these

across

enzymes,

inhibit one

decrease

would be on

the most

increase

serum propionate

or precursor

These workers pro¬

of

the urea

interfere with the

e.g.

in

interferes with

cycle

delivery of

ornithine or

the mitochondrial membrane.

the major pathway of propionate metabolism is

the mitochondrion,

drially.

of

in

a metabolite

to hyperammonemia.

the mitochondria and

loading

significant

isoleucine degradation

leads

this metabolite

in a

the buildup of

the pathway of

isoleucine

correlated with rises

ammonia detoxification and

that

that

likely

that portion of the

This hypothesis was

site of

urea

action

located within

for any

cycle which occurs

inhibitor

intramitochon-

confirmed in work by Glasgow and Chase

(90)

.

who demonstrated that 5 mM concentrations of propionate inhibited ureagenesis in vitro by 40 % in rat liver slices when ammonia,
citrulline or aspartate,

was the substrate.

Propionate,

but not

however,

had

no effect on either CPS I or OTC activities when measured in rat liver
homogenates.

They concluded that this inhibition of ureagenesis

(as well

as the hyperammonemia seen in patients with the organic acidemias)

was

due either to a direct inhibition of CPS I or OTC by a metabolite of
propionate,

or to inhibition of citrulline or ornithine transport across

the mitochondrial membrane,

or to depletion of one of the substrates

for the CPS I reaction.
Several intramitochondrial sites for action of such a metabolite
have been proposed.

Some workers have presented evidence from in vitro

experiments which favors the third possibility,

namely that a decreased

availability of one of the substrates of the CPS

I reaction leads to the

hyperammonemia.

demonstrated that

Cathelineau and colleagues

(91)

propionate decreased carbamyl phosphate concentration,
and ATP content.

citrullinogenesis,

They proposed that this decreased ATP concentration

and its consequent interference with CPS I activity could lead to hyper¬
ammonemia.

However,

Stewart and Walser

(92)

failed to find a decrease in

ATP levels in mitochondria isolated from rats injected with 20 mmoles/ kg
propionate or methylmalonate,

doses which caused significant increases in

blood ammonia.
Other workers have focused on the role of N-acetylglutamate
the required allosteric activator of CPS I.

Shigesada and Tatibana

initially described inhibtion of NAG synthetase by propionyl CoA,
Bachman

(93)

(NAG),
(60)

and

first proposed that such inhibition may account for the hyper

ammonemia seen in infants with propionic and methylmalonic acidemias.
If significant amounts of propionyl CoA build up behind the enzymatic
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blocks in these disorders,
could decrease,

NAG availability and,

hence,

CPS I activity

leading to hyperammonemia.

Coude and colleagues

(94)

working iri vitro with rat liver mitochondria

confirmed this inhibition and analyzed its kinetics extensively.

They

demonstrated that propionyl CoA was a competitive inhibitor of NAG
synthetase and that the K

is 0.71 mM,

well within the range of propionate

concnetrations observed in patients with these disorders.
Recently,

Stewart and Walser

these disorders,

(92),

working with an animal model

for

have demonstrated that rats injected with 10-20 mmoles/ kg

propionate or 20 mmoles/ kg methylmalonate and 1.5 g/ kg of an amino acid
mixture developed hyperammonemia.

Furthermore,

although ATP levels were

unchanged in mitochondria isolated from these rats,
activity were significantly decreased.

Moreover,

NAG content and CPS I

they demonstrated that

acetyl CoA concentrations were significantly decreased while acyl CoA's
(presumably propionyl and methylmalonyl CoA's)

were increased.

They

suggested that NAG availability was decreased either because of competitive
inhibition of NAG synthetase by propionyl CoA or from depletion of acetyl
CoA.

Thus,

NAG depletion was highlighted as the putative mechanism

for the hyperammonemia seen in patients with the inherited organic
acidemias.

However,

these workers failed to show any decrease in NAG

concentrations with injections of 10 mmoles/ kg methylmalonate,

a dose

v?hich led to significant decreases in acetyl CoA and an increase in
blood ammonia.

In addition,

methylmalonyl CoA has been shown not to

significantly inhibit NAG synthetase
Alternatively,

(60).

propionyl CoA may act as a substrate for NAG synthetase

leading to the production of N-propionylglutamate
effective as an activator for CPS I,

(NPG),

a compound less

which could compete with NAG for its

*
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CPS I binding site.

That NPG is a weak activator of CPS I was confirmed

by Coude and colleagues who demonstrated a
times the value obtained for NAG.

for NPG of 1.1 mM,

A buildup of propionyl CoA,

could result in the production of NPG instead of NAG,

ten

therefore,

and consequently

CPS I activation would be decreased and hyperammonemia would occur.
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Part II:

The Organic Acidemias and Hyperammonemia:

Experimental

Introduction
All of the work summarized in the Review section suggests that
organic acid accumulation impairs the intramitochondrial synthesis of
carbamyl phosphate by decreasing the concentrations of CPS
(ATP)

or activators

activator

(NPG).

hypothesis,

(NAG),

I substrates

or by favoring the synthesis of a much poorer

The present studies were undertaken to examine another

namely that a metabolite in the pathway of branched-chain

amino acid degradation directly inhibits one of the urea cycle enzymes.
I have demonstrated that several acyl CoA's significantly inhibit CPS I
activity in rat liver homogenates,
enzyme,

disrupted mitochondria,

as well as in human liver homogenates.

and purified

*
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t
Materials and Methods

125 g female rats were purchased from Camm Laboratories in Wayne,
and were fed a standard commercial diettation and livers were quickly excised.

Rats were sacrificed by decapi¬
Liver for homogenates was quick

frozen in dry ice and stored at -90&C until needed.

Human liver was

obtained from autopsy specimens within one hour of death,
and stored.

5%

(w/v)

N.J.

quick frozen

homogenates for CPS I and arginase assays and 0.5%

homogenates for OTC assays were prepared daily from frozen liver which
was weighed wet and homogenized in distilled water.

Preparation of Mitochondria
Mitochondria were prepared from fresh rat liver using the method of
differential centrifugation of Loewenstein
colleagues

(96).

(95)

as modified by Fenton and

Liver from decapitated rats was excised,

and suspended in a solution

(SET solution)

weighed wet,

containing 0.25 M sucrose,

17 mM Tris-HCl and 1 mM Na-EGTA pH 7.4 to make it

15% weight/ volume.

The liver was minced with scissors and then homogenized with six to nine
passes at 2100 rpm.

The homogenate was centrifuged at 5000 rpm for one

minute to remove the nuclear pellet and whole cells.
recentrifuged for two minutes at 12,000 rpm.

The supernatant was

The pellet containing

mitochondria and lysosomes was suspended in SET solution,
starting liver.
solution),
minutes.

An equal volume of digitonin solution

1 ml per gram

(1.75 mg/ml in SET

was added and the mixture gently agitated at 4°C for two
This was then diluted to 5 ml/ gram starting liver and spun

at 12,500 rpm for 4.5 minutes.

The supernatant was removed and the

,
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pellet was washed

centrifuged

about

for

twice

in SET solution,

5.5 minutes.

1 g mitochondria per

The yield

100 g

2 ml/ gram starting

liver

from this procedure was

and

generally

liver.

Purified Enzyme
Purified CPS

enzyme was

(pH 8.0),

acetate,

prior

I was

stored

obtained

frozen at

-90°C

2 M ammonium sulfate,

and

to use

as

a gift

in a buffer

the

cations were

The

removed by

equilibrated with

0.05 M Tris-acetate buffer,

a one ml

with two volumes of

three minutes

liters)

tion for

the

100 X g.

glycerol.

to

top of

3 minutes

tuberculin-type

this buffer

was brought

placed on

at the

at

a

the

at

(98).

G-50

pH

syringe.

(fine)

of

column.

The

Sephadex

and a column

for

(10-100 micro¬

100 microliters with buffer and

enzyme was

100 X g and then diluted

the procedure unless

just

column was washed

enzyme preparation

final volume of

acetate

Sephadex was

(4°C)

The

collected by

in buffer

No dithioerythritol or dithiothreitol was

end of

thawed

and then packed by centrifugation

A sample

The

0.01 M magnesium

technique of

8.0

(97).

50 mM Tris-

sample was

the

described by Lusty

into

containing

frozen

centrifugation as

was poured

Carol Lusty

0.1 M sodium acetate,

2 mM dithioerythritol.

and

from Dr.

centrifuga¬

containing

added to

the

50%

enzyme

noted below.

Hepatic Enzyme Assays
CPS

I

activity

measurement of

NH^HCO^.

added to

(99).

5% homogenate,

The

liver homogenates was

citrulline

of Erown and Cohen

0.01 ml

in

latter

initiate

determined by the

synthesis

using

The

assay volume was

final

10 mM NAG,

a modification of

20 mM ATP,

three reagents were

the reaction and also

0.1 ml

20 mM MgCl^,

added as part of

contained

colorimetric

the method

containing

and

50 mM

a mix which was

40 mM Tris-HCl

buffer,

-

*
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(pH

7.5),

9 mM ornithine,

reaction was

at

37°C;

ay pH

7.2.

acid.

without NAG gave

125 ml

and

g

standards

A

values.

was

of

2.5

All

study.

Control

for

both

reactions were

assay

rat

7.2.

in

sample

in rat

liver

of

is

tri¬

and blank

solution

the

(1.85

added

g

to

solution

1:2 with water.

30 minutes

to

and

then

standard

initiation of

the

control

in

homogenates

from other

diacetyl

sulfuric acid)

from a

and compared

ro

1 volume

concentrated

for

used.

the method of

250 ml water

liver homogenates

activity

185)

in

acid

N HC1 diluted

tubes

tubes

ranged

each

from 2.0-2.8

from 0.8-1.0 umoles/

authors

(101).

in isolated mitochondria was performed

after gentle

sonification

the mitochondria at 4°C

A zero-time blank was

which

125 ml

0.1

10%

assay mixture,

contained

in duplicate with

in human

I

from the

2 volumes

just prior

liver mitochondria assayed at

chondrial protein,

ml

10 micrograms were made

conditions

a Branson cell disrupter

and

acid and

in agreement with data

above

Final pH was

run

activities

Measurement of CPS

using the

the

added

umoles/hr/mg protein and

hr/mg,

to

0.15

a boiling water bath

Inhibitors were

assay.

0.1 ml

final

ten minutes

zero-time blank was

ammonium sulfate

citrulline

into

read

a

The

for

zero-time blank,

solution which

7.5% NaCl)

ferrous

15 mg%

tubes were put

cooled.

3 ml of a

50 ml

1.25

which contained

addition of

and hence

contained

concentrated phosphoric

Citrulline

All

and

(200 mg in

antipyrine

the

incubated

carried out using a modification of

Each tube

0.85 ml of water,

monoxime

terminated by

similar results

(100).

units purified bovine OTC.

A boiled enzyme blank,

Color development was

Archibald

0.5

Reaction mixtures were

reactions were

chloroacetic

and

used.

37°C were

Control

9.6-12

in agreement with other

(setting

for

30

1 on

seconds.

activities

for

umoles/hr/mg mito¬

authors

(101) .

.
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Control activity

is

30°C was

4.0 umoles/hr/mg.

in agreement with other work

CPS

the

I

above

A280'
of

at

activity

(58).

Control

activity was

in rat

for a

The

homogenate,

final

120 umoles/hr/mg,

synthesis

assay volume was

10 mM ornithine

was

incubated

the

addition of

for

carried out as

and

15 minutes

0.1 ml

10%

from the

activity

as

0.1 ml

37°C and

except

assay.

in rat

contained

of the above

incubation mix.

37°C and the

reaction was

trichloroacetic acid.

of

the

assay mixture,

reaction was

0.05%

The mixture

terminated by

Color development was

tube

contained

activity was

synthesis by

1% bovine

assay mixture

Snodgrass

0.01 ml of

67

0.9 ml of

umoles/hr/mg,

liver homogenates was measured

was preincubated with

and

colorimetric

(101).

(101).

0.3 M NaCl,

the

that each

method of Nuzum and Snodgrass

0.05 ml

containing

Control

colorimetric determination of urea

0.09 ml

the

described by Nuzum and

trichloroacetic acid.

described above

0.1 ml

Arginase

The

in agreement with

10 mM carbamyl phosphate.

at

in agreement with other authors

cine,

solution with a concnetration

liver homogenates was measured by

determination of citrulline

water and

1.0

from the

(97).

OTC activity

(101).

determined using

Protein content was determined

assum;*-n9 an 0D reading of

other work

temperature dependence

in purified enzyme preparations was

assay conditions.

1 mg/ml.

This

0.1 ml

0.2 ml

a modification of

0.01 ml of a

This mix was

assayed

the

Color development was

the

liver homogenate

0.5 ml

for one

375 mM arginine,

terminated by

5%

serum albumin,

0.1 M MnC1^

using the

pH

for

0.07 M gly¬

hour at

9.5,

and

37°C.

0.1 ml

10 minutes

addition of

0.1 ml

of

carried out by mixing

2 ml of an acid reagent containing

18 ml

of

at

20%

0.2 ml
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concentrated

0.2 ml

95%

sulfuric

0.1 M FeCl^,

ethanol.

taining

25 mg%

water bath

each

Urea

urea/hr/mg,

ture

0.1 ml

in 0.1

3%

and compared

All

to

N NaOH.

and then

was

added and

was

read

2

incubated

for each

for

sample

authors

added

2%

incubated

Reagent

compared

solution

in

con¬

in a boiling

Ar<„ was
540

(102),

to

sodium tartate,

for

read

for

500 umoles

unless

5 ml

and

10 minutes

(Fisher),

30 minutes more

and

and

(101).

samples were

0.5 ml

N Phenol

acid

activity v/as

Lowry

This mixture was

0.5 ml

Control

the method of

Diluted

1% CuSO^,

stock

then cooled.

standards.

determined by

from a

tubes were placed

the dark and

in agreement with other

0.5 ml

concentrated phosphoric

1-phenyl-l,2-popane dione-2-oxime

N HC1.

in

noted above.

containing

54 ml of

standards were prepared

urea

Protein was

in 0.1

and

for one hour

sample

otherwise

acid,

diluted

of a

solution

50 ml

at

as

2%

Na CO

room tempera¬

1:1 with water,

at room temoerature.

to known concentrations

A^,.
625

of bovine

serum albumin.

Inhibitors

Potential

inhibitors

selected

pathway of

isoleucine degradation,

were

just prior

added

pH of

was

the

no

final

the

study were organic

as well

initiation of

as

acids

their CoA esters.

the

assay unless

significant difference

from control.

from Sigma.

Methylcitrate was

The CoA esters were purchased

Propionyl CoA was

the

synthesized as

synthesized

acids

a gift

the

Inhibitors

gift of Dr.

there

and

iso¬

from Dr.

Wayne

Fenton

described below.

from propionic

anhydride

The

and

from PL Biochemicals with the

exception of methylmalonyl CoA which was

and propionyl CoA which was

The organic

in

specified.

assay mixture was measured with each inhibitor

leucine were purchased

Tanaka.

to

for

(Eastman)

Kay
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and Coenzyme A

(PL Biochemicals)

of Flavin and Ochoa

(103).

1 M ammonium bicarbonate
of ethanol.

following a modification of the method

500 mg of coenzyme A was added to 30 ml of

(pH 9.0),

7 ml of propionic anhydride and 33 ml

The propionyl CoA formed was extracted three times with ether,

adding an equal volume of ether and water.
by vacuum suction extractions.

The excess ether was removed

After the final extraction,

CoA was lyophilized and resuspended in 4 ml of water.

the propionyl

The concentration

of propionyl CoA in the final solution was calculated by measurement of
the A232'

us^n<? an extinction coefficient of 7.85.

Calculation of Enzyme Inhibition
Calculations of enzyme inhibition were complicated by the fact that
the acyl CoA's inhibited the colorimetric reactions used to determine
CPS I,

OTC,

and arginase activities.

color development,
(i.e.

To correct for suppression of

propionyl or other CoA's were added to assay blanks

without homogenate),

carried through the assay procedure,

standard concentrations of citrulline and urea,
the color development process.

added to

and finally carried through

These were compared to similar standards

containing no CoA esters to obtain an estimate of color suppression.
Enzyme inhibition was calculated using the formula
with inhibitor)

=

(Control activity)

(1 - fraction color suppression),
tion.

X

(Observed activity

(1 - fraction of enzyme inhibition)

solving for fraction of enzyme inhibi¬

Figure 5 demonstrates the effect of propionyl CoA at concentra¬

tions of 0,
citrulline.

1,

3,

and 8 mM in suppressing colorimetric determination of

At each concentration of propionyl CoA,

residual color developed at

(i.e.

the fractional

(1 - fraction color suppression))

X
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is equal for all concentrations of citrulline:
0.95;

3 mM,

0.85;

and 8 mM,

0.65.

for 1 mM propionyl CoA,
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CITRULLIME

{/jlq)

Figure 5.

Suppression of the

determine

the rate of citrulline synthesis by propionyl CoA.

Calculations of CPS
by the

I

inhibition by propionyl CoA were

fact that CoA esters

to measure

color development reaction used to
complicated

inhibit the colorimetric reaction used

CPS I activity as well as

the enzyme.

estimate of the amount of color suppression,

To obtain an

various

concentrations

of propionyl CoA were added to known amounts of citrulline,
through the color development process,
citrulline standards.

(i.e.

was equal for ail concentrations of
0.95;

3 mM,

0.85,

run

then compared to

For each concentration of propionyl CoA,

the fractional residual color
CoA,

and

and 8 mM,

1 -

fractional

citrulline:

0.65.

for

color suppression)
1 ml 1 propionyl

.

Results

Selective Inhibition of CPS I Activity in Rat Liver by CoA Esters
The effects of various metabolites on the iii vitro activities of
three urea cycle enzymes were tested.
demonstrate that neither propionate,

The results shown in Table 1
methylmalonate,

tiglate,

methylcitrate,

nor isoleucine at concentrations of 10 mM inhibited CPS I or OTC activi¬
ties in rat liver homogenates.

Further,

neither CoA nor the CoA esters

of several of these organic acids affected the activity of OTC or
arginase.

In sharp contrast to these latter results,

however,

CPS

I

activity was regularly and significantly impaired when 10 mM concentrations
of CoA,

tiglyl CoA,

methylmalonyl CoA,

or propionvl CoA were added at the

point of initiation of the enzyme assay.

Table 1 shows data from a

single representative experiment in which free CoA reduced activity
by 35%,

the acyl CoA's by considerably more.

the most potent inhibitor,

Propionyl CoA was regularly

reducing activity by 72% in this study and

by an average of 71 + 5% in experiments with three different rat livers.

Concentration-Dependent and Time-Dependent Inhibition of CPS I Activity
Using propionyl CoA as the model inhibitor in further experiments,
I demonstrated that the inhibition of CPS
in isolated mitochondria,

and of purified enzyme .is a function of the

propionyl CoA concentration.
(0-10 mM)

I activity in crude homogenates,

When varying concentrations of propionyl CoA

were present only during the ten minutes of enzyme assay,

inhibition of CPS I activity increased from 35% at 1 mM to 70% at 10 mM
(Figure 6).

At each concentration of propionyl CoA tested,

inhibition
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Table 1:

Inhibition of urea cycle enzymes by •various metabolites in
pathway of isoleucine degradation

Inhibition of ;Enzyme Activity

OTC

CPS I

Compound

(%)

Arginase

propionyl CoA

72

(4)

0

(2)

0

methylmalonyl CoA

66

(2)

0

(2)

*

tiglyl CoA

49

(2)

0

(2)

*

CoA

35

(2)

0

(2)

0

methylcitrate

4

(2)

0

(2)

*

isoleucine

2

(2)

0

(2)

*

tiglic acid

0

(2)

0

(2)

*

methylmalonic acid

0

(2)

0

(2)

*

propionic acid

0

(2)

0

(2)

0

(2)

(1)

(1)

Urea cycle enzyme activities in rat liver homogenates were assayed in the
presence of 10 mM inhibitor added just prior to the initiation of the assay.
The data presented are the averages of duplicate tubes run in a single
representative experiment.
OTC 67 umoles/hr/mg;

Control activities were:

and arginase 500 umoles/hr/mg.

CPS

I

2.6 umoles/hr/mg?

The numbers in the

parentheses refer to the number of experiments done with each inhibitor at
this concentration.

* = not tested.

was slightly greater with the crude homogenates and isolated mitochondria
than with purified CPS I,

but the difference among the various tissue

preparations was small compared to the overall magnitude of the inhibitory
effect.
When homogenates were incubated with propionyl CoA prior to initiating
the CPS I assay,

the inhibitory effect was noted to be time-dependent.

'

-
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o

[PROPIONYL CoA ] mM

Figure

6.

Concentration-dependent

inhibition of CPS I by propionyl

CoA. CPS I activity in crude homogenates, in disrupted mitochondria,
and of pure enzyme from rat liver was measured in the presence
of varying concentrations of propionyl CoA (0-10 mM), added at the
point of initiation of the enzyme assay.
Control activities were:
homogenate,
pure enzyme,

2.4 umoles/hr/mg;
120 umoles/hr/mg.

mitochondria,

11 umoles/hr/mg;

and

-

■

'
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In the experiment shown in Figure 7,

homogenates were incubated with 2.5 mli

propionyl CoA and 25 mM NAG for 0-30 minutes and then were assayed for
CPS I activity in the presence of 1 mM propionyl CoA.

The data demonstrate

that the inhibitory effect increased linearly from 45% with no prior
incubation

(i.e.

10 minutes of total exposure)

to 66% when the enzyme

was incubated with the inhibitor for 30 minutes prior to assay
40 minutes of total exposure.

(i.e.

The linearity of the curve suggests that

with total exposure times greater than 40 minutes,

CPS

I activity would

likely have been inhibited even more.
A recent paper

(94)

reported that the inhibition of CPS

I activity

in isolated rat liver mitochondria by 10 mM propionyl CoA was only about
c
15% at 30 C,

significantly less than the 70% inhibition seen in the present

experiments conducted at 37°C.

To determine if these disparate results

reflected the different temperatures used,
both 30°C and 37 °C.

Table 2 shows that CPS

I carried out experiments at
I activity in isolated

mitochondria was inhibited comparably by 3 mM concentrations of
propionyl CoA at both temperatures

Table 2:

(43% at 30cC;

40% at 37cC).

Effect of incubation temperature on inhibition of CPS I activity
in disrupted mitochondria by propionyl CoA
CPS I Activity

Temperature

(UC)

control

(umoles/hr/mg)

+ 3 mM propionyl CoA

30

7.2

4.1

37

4.0

2.4

CPS I activity was assayed in disrupted mitochondria at 30° C and 37'" C
in the presence and absence of 3 mM propionyl CoA.

Data shown are averages

of duplicate tubes from one of two identical experiments.
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MINUTES OF TOTAL CPS I EXPOSURE
TO PROPIONYL CoA
Figure

7.

Time-dependent

activity in crude
of

inhibition of CPS I by propionyl

rat liver homogenates was assayed in

1 mM propionyl CoA after incubation of the enzyme with

propionyl CoA.
vary

Control activity was

in control incubations

CoA.

CPS I

the presence
2.5 mM

205 umoles/hr/mg and did not

from 0-30 minutes without propionyl CoA.

*

■
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Mechanism of Propionyl CoA Inhibition
To characterize further the mechanism by which propionyl CoA impairs
CPS I activity,

Michaelis-Menten kinetic analyses were carried out in

rat liver homogenates with each of the enzyme's substrates
and bicarbonate).

(ATP,

Double reciprocal transformation of substrate vs.

velocity curves yielded linear plots from which the apparent K
V

max

ammonium,

's could be calculated.

As shown in Table 3,

reduced the maximal velocity of CPS

m

's and

3 mM propionyl CoA
J

I activity by about 50% regardless

of which of the enzyme's substrates was varied.

Significnatly the apparent

K 's for each substrate were not affected by the propionyl CoA.
m

Table 3:

Kinetic parameters of rat liver CPS I in the presence and absence
of 3 mM propionyl CoA

control

ATP

NH

K

V
(umoles/hr/mg)*
—max--—

Substrate

+ 3mM propionyl CoA

(mM) *

—m-

control

+ 3mM propionyl CoA

2.09

1.04

3.2

3.3

1.95

1.02

0.53

0.45

2.53

1.38

3.2

2.7

+
4

HCO~

*Kinetic parameters were determined in rat liver homogenates by varying the
concentration of one substrate while keeping the other two substrate con¬
centrations constant.
K 's and V
's were derived from plots of
1/velocity vs.

l/substra5!e concentration.

varied as follows: for ATP 1,
50 mM; and for HCO~ 1, 2, 10,

Substrate concentrations were

2, 4, and 20 mM;
and 50 mM.

for NH^ 0.25,

1,

2,

5,

and

'

■
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To insure that the effect of propionyl CoA on CPS I was not secondary
to the described inhibition of NAG synthetase,
all of our assays was 10 mM,

the NAG concentration in

100 times its reported K

(98).

Furthermore,

3

increasing the concentration of NAG to 100 mM did not decrease the
magnitude of the inhibitory effect of propionyl CoA seen in homogenates,
isolated mitochondria,

or purified enzyme.

In experiments with purified enzyme from rat liver,
of dithiothreitol

(DTT)

the addition

to the enzyme after passage through the Sephadex

column reduced the degree of inhibition produced by propionyl CoA.
Table 4 demonstrates that addition of 2 mM DTT reduced inhibition of
CPS I by 3 mM propionyl CoA from 57% to 24%.

Increasing the concentration

of DTT to 4 mM had no further effect.
To determine the reversibility of propionyl CoA inhibition of CPS I,
purified enzyme was incubated with 3 mM propionyl CoA for 15 and 30
minutes, passed through a Sephadex column to remove the propionyl CoA
and then assayed.

The data shown in Table 5 demonstrate that removal

of the propionyl CoA from the assay mixture led to complete loss of
its inhibitory effect.

Inhibitory effect of 3 mM propionyl CoA ■with varying concentrations
(DTT)
. .
CPS I activity (umo1e s/hr/mg)

Table 4:

of dithiothreitol
DTT

(mM)

control

+ 3 mM propionyl CoA

0

72

31

2

83

63

4

76

59

CPS I activity was assayed in pure enzyme preparations to which varying
concentrations of DTT were added after passage of the enzyme through the
Sephadex column used to desalt the enzyme from the storage buffer.
Activity
with each preparation was measured in the presence and absence of 3 mM
propionyl CoA.
Data are from one of two identical experiments with
similar results.

*
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Table 5:

Reversibility of propionyl CoA inhibition of CPS I
CPS I activity

Incubation time

(mins)

control

(umoles/hr/mg)

+ 3 mM propionyl CoA

0

74

15

66

70

30

80

76

CPS I activity was measured using pure enzyme preparations incubated for
varying times with 3 mM propionyl CoA,

passed through a Sephadex column to

remove the propionyl CoA and then assayed.

Control preparations incubated

without propionyl CoA were also assayed.

Results with Human Liver
Finally,

very similar results were obtained when CPS I activity was

assayed in homogenates of post mortem human liver.
had no effect on human hepatic CPS I activity,
at concentrations of 1 mM or greater,

Thus,

10 mM propionate

whereas propionyl CoA,

impaired CPS I activity in human

liver to an extent virtually identical with that noted for rat liver.
For example,

exposure of the human liver homogenate to 3 mM propionyl CoA

reduced CPS I activity by 48%,

an effect indistinguishable from the 52%

inhibition observed under identical conditions with rat liver.
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Discussion

Hyperammonemia has

been a common

finding

disorders of organic acid metabolism,

and 0<-methylacetoacetic acidemias.

as yet unidentified,

the metabolic

it

is

likely

indicates

availability or

the

the allosteric activator,

in an attempt

The data presented in this

inhibitory effect,

various

acyl

namely

CoA's.

of

propionyl CoA,

chondria,

In

studies

inhibition

and purified

the

using

in rat

enzyme was

in these preparations

CoA to

at

These

in which

children with

link

the primary

the

either by decreasing

substrates,

ATP,

differ

mitochondria by only

temperature dependent

15%

three

I

tiglate,

urea cycle

I

to be

increased

and

enzymes measured,

activity,

liver homogenates,

shown

activity by

propionate,

the most potent of

from those

at

since

inhibition of CPS

the

or

but not

these

that of

CoA esters,

disrupted mito¬

concentration-dependent.

from about

35%

at

1 mM propionyl

10 mM.

results

to

reaction.

acids

rep rted

10 mM propionyl CoA inhibited CPS

equivalent

I

inhibited CPS

Inhibition

70%

impaired

inhibition of CPS

the organic

significnatly

arginase.

CPS

contributes

paper demonstrate a different kind of

methylmalonate had no effect on

their CoA esters

the

a direct

While

is

to

is

secondary biochemical

action of one of

NAG,

hyperammonemia

characteristic of

that ureagenesis

impairing

this

three

methylmalonic,

its occurrence

in organic acid metabolism with this

abnormality

OTC or

cause of

that

is

Previous work done

infants with

namely propionic,

The

encephalopathy which

these disorders.

defects

but

in

30 C.

I

in a previous

activity

(92)

in disrupted

This difference was

in the present experiments

I was demonstrated

study

at both

shown not

to be

significant

30° C and

and

3/ C.

I

.

(;

The difference may be explained if the assays in the previous work
were run in the presence of mercaptoethanol or another sulfhydryl reagent
since I have shown that these agents protect CPS I
propionyl CoA.

Furthermore,

from inhibition by

the control activity measured by these

o

authors was only 50% of that seen at 30 C in the present experiments.
This may reflect the presence of another inhibitor in the assays which
complicated evaluation of CoA ester inhibition.
The degree of inhibition that was demonstrated with 10 mM propionyl
CoA is large enough to account for the hyperammonemia observed in_ vivo
since patients with ammonia intoxication due to primary CPS I deficien¬
cies have been reported with as much as 40% residual CPS I activity
In addition,

the preliminary studies presented here,

was incubated with homogenates prior to assaying CPS

(104).

in which propionyl CoA
I activity,

indicate

that the inhibition of CPS I by propionyl CoA may also be time-dependent.
Thus,

the concentration of propionyl CoA needed to achieve marked

inhibition of CPS I activity might be less than the
regularly employed to achieve 60% inhibition.

10 mM concentrations

In fact,

incubation of

homogenates with 2.5 mM propionyl CoA for 30 minutes followed by assay
in the presence of 1 mM prcpionyl CoA resulted in 66% inhibition of
CPS I activity.
disorders,

If the time that propionyl CoA builds up in these

and hence the time of exposure to CPS I,

is taken into account,

propionyl CoA concentrations closer to the serum concentrations of
propionate observed in patients with propionic acidemia will result in
60% inhibition or more.
It should be stressed that my results cannot be explained by the
previous data which attributed the hyperammonemia to decreased availa¬
bility or action of NAG,

since the present assays were run in the presence
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of 10 mM NAG,

100 times the reported K

(97).

In addition,

increasing

cl

the concentration of NAG to 100 mM had no effect on the degree of inhibition.
The data obtained in these in_ vitro studies is consistent with
what little in vivo information does exist.

First,

despite the lack

of any measurements of intramitochondrial CoA concentrations in the
tissues of patients with these inherited organic acidemias,
Walser

(92)

have shown that acyl CoA's

malonyl CoA's)

Stewart and

(presumably propionyl and methyl-

increase in mitochondria isolated from rats injected with

20 mmoles/kg propionate or methylmalonate.

Since millimolar concentra¬

tions of the free acids have been reported in the blood

(34) ,

it is

plausible that the concentration of the CoA esters employed in our experi¬
ments may accumulate intramitochondrially iri vivo.
particular relevance,

(105)

and of

significantly reduced CPS I activities have been

reported in children with these organic acidemias.
Keisel

Second,

In 1969,

Kirkmann and

described a child with hyperammonemia and a selective

deficiency of CPS I activity to 50% of control values who was subse¬
quently shown to have methylmalonic acidemia.

More recently,

Harris and

colleagues reported selective CPS I deficiency to 20% of control values
in a child with propionic acidemia

(106).

It is unlikely that these

CPS I values represent coexisting primary metabolic defects;

low

rather it is

likely that they are secondary to the defect in organic acid metabolism.
Thirdly,

other workers

(107,108)

have proposed that the hypoglycemia

and hyperglycinemia often observed in patients with these organic
acidemias may result from the intramitochondrial effects of CoA esters
on gluconeogenesis and glycine cleavage,

respectively.

It is,

therefore,

attractive to propose that all of the major secondary biochemical ab¬
normalities observed in the organic acidemias may reflect CoA ester-

V

‘
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8

mediated disturbances of selected mitochondrial

functions.

the present data,

can explain the hyper¬

unlike those of other groups,

ammonemia observed in all three disorders since tiglyl,

Finally,

methylmalonyl,

and propionyl CoA's all exhibited significant inhibition of CPS I.
Inhibition of NAG synthetase,

on the other hand,

cannot explain the

hyperammonemia seen in patients with methylmalonic acidemia since
methylmalonyl CoA inhibits this enzyme only to a small degree.
These results provide little information as to the precise bio¬
chemical mechanism by which CoA and its derivatives impair hepatic CPS
activity.

I

Results of the Michaelis-Menten analyses indicate that these

CoA's do not compete with any of this complex enzyme's substrates for
their binding sites since only the V

mcix

by propionyl CoA.

's and not the K

m

's were affected

The ability of dithiothreitol to decrease the degree

of inhibition by propionyl CoA suggests that the CoA's act by interacting
with sulfhydryl groups on the enzyme,

either to alter the active site

or change the conformation of the enzyme.

The importance of sulfhydryl

groups in CPS I has been studied and seems to be related to the stabiliza¬
tion of various conformations.

Some sulfhydryl reagents like cysteine

result in quick inactivation of the enzyme,

which some authors

(109)

suggest may occur by the breaking of disulfide bonds leading to the
dissociation of the dimer.
NAG

(110).

This inactivation requires the presence of

Since NAG effects a conformational change on CPS I,

this

change in tertiary structure may unmask a key sulfhydryl group with
which cysteine can react.
ethanol,

dithiothreitol,

the enzyme

(97,111).

Other sulfhydryl reagents,
and dithioerythritol,

such as mercapto-

have been shown to stabilize

The difference between these two groups of sulf-

'

.
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hydryl agents may be due to steric factors or the strength of the -SH
groups themselves.
protected CPS

In these experiments,

dithiothreitol partially

I from inhibition by propionyl CoA.

may be acting to inhibit CPS

Propionyl CoA,

then,

I by forming a propionyl CoA-enzvme complex

involving sulfhydryl groups or by accelerating the conformational change
to its inactive form.

If the latter mechanism is correct,

one would

predict that preincubation of CPS I with propionyl CoA would lead to
inhibition even if the propionyl CoA were to be removed prior to
assaying.
(Table 5)
mixture,

The inability to demonstrate such an effect in these experiments
may be secondary to the absence of NAG in the preincubation
but it may argue against the formation of stable enzyme-

inhibitor complexes.
The hyperammonemia seen in patients with inherited organic acidemias
appears to occur as the result of the buildup of acyl CoA intermediates
in response to an amino acid load.

The present data taken together

with previous work suggests that the acyl CoA's may work at two sites:
namely 1)

to inhibit directly CPS I and 2)

and secondarily decrease CPS I activity.
the availability of ATP,

to decrease NAG availability
In addition,

increased nitrogen turnover,

factors such as
and the rate of

removal of these acyl CoA's may be important in the pathogenesis of the
hyperammonemia.
The relationship between the pathogenesis of the hyperammonemia seen
in inherietd disorders of organic acid metabolism and that seen in other
disorders such as Reye's Syndrome and hypoglycin toxicity
vomiting sickness)

remains to be demonstrated.

Certainly many clinical

and biochemical similarities exist including vomiting,
coma as well as hypoglycemia and hyperammonemia.

(Jamaican

lethargy,

and

If the toxic agent
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i

in each of these disorders inhibits one of the enzymes important for
branched-chain amino acid metabolism,

significant concentrations of acyl

CoA's may accumulate.

the toxic agents themselves may be

Alternatively,

metabolized to short chain fatty acids which could be converted to CoA
esters.

In either case,

this buildup of acyl CoA's may inhibit CPS I and

lead to hyperammonemia.
Treatment of children with propionic,

methylmalonic,

and o(-methyl-

acetoacetic acidemias consists of a diet low in the amino acids that enter
the Krebs Cycle through methylmalonate:
and threonine.

valine,

isoleucine,

In patients who are recognized early,

diet has achieved excellent results

(35) .

institution of such a

In patients where these

disorders are unexpected and in whom hyperammonemia occurs,
tion of peritoneal dialysis is essential.

methionine,

early institu¬

If a decrease in INAGavaila-

bility is important in the pathogenesis of the hyperammonemia,
of L-arginine and carbamylglutamate

(since NAG has been shown to break

down when administered intraperitoneally in rats)
hyperammonemia.

infusion

may ameliorate the

To the extent that a direct effect on CPS I by increased

levels of acyl CoA's is important iri vivo,

administration of carbamyl¬

glutamate is unlikely to decrease ammonia levels,

in light of the present

work which fails to demonstrate a decrease in inhibition with increased
concentrations of NAG in_ vitro.

General support in the form of dialysis

and removal of the offending amino acids may give some benefit.
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